List of Excipients in Branded Drug SINGULAIR

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Merck Sharp & Dohme Corp	SINGULAIR	montelukast sodium	0006-3841	HYDROXYPROPYL CELLULOSE
Merck Sharp & Dohme Corp	SINGULAIR	montelukast sodium	0006-3841	MAGNESIUM STEARATE
Merck Sharp & Dohme Corp	SINGULAIR	montelukast sodium	0006-3841	MANNITOL
Rebel Distributors Corp	SINGULAIR	montelukast sodium	21695-565	ASPARTAME

Singulair Excipient Strategy and Commercial Opportunities for Montelukast

Last updated: August 7, 2026

Singulair contains montelukast sodium and is available as 10 mg film-coated tablets, 4 mg and 5 mg chewable tablets, and 4 mg oral granules. The core montelukast patent estate has expired, generic competition is established, and the commercial opportunity is concentrated in differentiated excipient systems rather than basic active-ingredient exclusivity. The strongest opportunities are aspartame-free pediatric products, lactose-free tablets, improved taste masking, orally disintegrating formats, sprinkle granules, and region-specific formulations that reduce manufacturing or regulatory complexity.

What is Singulair and which dosage forms use montelukast?

Singulair is Merck's brand for montelukast, a selective cysteinyl leukotriene receptor antagonist used for asthma and allergic rhinitis. Montelukast sodium is administered orally and is not a biologic, so biosimilar regulation does not apply.

Singulair presentation	Strength	Typical patient segment	Primary excipient strategy
Film-coated tablet	10 mg	Adults and adolescents	Lactose-based direct compression, coating, tablet robustness
Chewable tablet	4 mg	Children aged 2 to 5 years	Mannitol, sweetener, flavor, rapid disintegration
Chewable tablet	5 mg	Children aged 6 to 14 years	Mannitol, sweetener, flavor, chewability
Oral granules	4 mg	Children aged 12 months to 5 years	Unit-dose granulation, taste masking, sprinkle administration

The FDA-approved labeling identifies montelukast sodium as the active ingredient and describes different inactive-ingredient systems for each presentation.[1] The dosage-form split creates several separate formulation markets rather than one generic tablet market.

What excipients are used in Singulair formulations?

Singulair's excipients vary by strength and dosage form. The listed ingredients generally include lactose or mannitol as a diluent, microcrystalline cellulose as a compression aid, croscarmellose sodium as a disintegrant, hydroxypropyl cellulose as a binder, magnesium stearate as a lubricant, and flavoring or sweetening agents in pediatric products.

Singulair 10 mg film-coated tablets

The 10 mg tablet uses a conventional immediate-release tablet platform. Key excipient functions include:

• Lactose monohydrate: filler and compression aid.
• Microcrystalline cellulose: dry binder and tablet-strength contributor.
• Croscarmellose sodium: superdisintegrant.
• Hydroxypropyl cellulose: binder.
• Magnesium stearate: lubricant.
• Film-coating polymers and pigments: protection, identification, and swallowability.

This formulation is technically mature. A generic manufacturer can normally use standard direct-compression or dry-granulation equipment, subject to product-specific process development and bioequivalence requirements.

Singulair 4 mg and 5 mg chewable tablets

The pediatric chewables use a non-lactose diluent system centered on mannitol. The formulation also uses sweetener and cherry flavor components, with croscarmellose sodium supporting rapid tablet breakup.

Commercially relevant excipient attributes include:

• Low hygroscopicity to preserve tablet hardness and stability.
• Cooling mouthfeel from mannitol.
• Controlled sweetness without excessive aftertaste.
• Flavor compatibility with montelukast.
• Low friability during packaging and distribution.
• Rapid disintegration without chalkiness.

Aspartame is a material consideration because the Singulair chewable labeling identifies it as a source of phenylalanine.[1] An aspartame-free product could target patients with phenylketonuria and consumers seeking alternative sweetener systems. The opportunity is commercially narrow but technically differentiated.

Singulair 4 mg oral granules

The 4 mg granules are designed for administration directly into the mouth or with selected soft foods. This presentation has a different risk profile from chewable tablets:

• Particle-size distribution affects dose uniformity and mouthfeel.
• Surface coating affects taste masking and dissolution.
• Moisture control affects granule flow and stability.
• Unit-dose sachets support adherence and reduce dosing errors.
• Food compatibility must be demonstrated for the intended administration method.

Granules can be attractive in markets where caregivers prefer sachets over tablets. The principal development challenge is balancing taste masking with rapid release of montelukast.

What excipient strategy is strongest for generic montelukast?

The best strategy depends on the target segment. A low-cost 10 mg tablet and a premium pediatric chewable require different excipient priorities.

Target product	Preferred excipient direction	Commercial rationale
Low-cost adult generic	Lactose or lactose-free direct compression	Manufacturing efficiency and broad supply availability
Lactose-free tablet	Mannitol, MCC, dibasic calcium phosphate, or co-processed filler	Differentiates from lactose-containing products
Pediatric chewable	Mannitol or isomalt with high-intensity sweetener and flavor system	Improves palatability and caregiver acceptance
Aspartame-free chewable	Sucralose, acesulfame potassium, steviol glycosides, or blended system	Addresses phenylalanine concern
Oral granules	Polymer-coated particles or taste-masked micronized drug	Supports pediatric administration
Orally disintegrating tablet	Mannitol-based porous matrix with superdisintegrant	Creates a differentiated swallow-free product
Moisture-sensitive format	Low-water-activity excipients and high-barrier packaging	Improves stability and shelf life

A manufacturer should avoid unnecessary excipient complexity in a conventional generic. Every novel excipient, unusual coating, or nonstandard manufacturing step can increase regulatory documentation and comparability work. Differentiation is more defensible when it solves a clear patient or manufacturing problem.

What formulation patents protect montelukast products?

The original Singulair patent estate protected montelukast and related pharmaceutical compositions. The core U.S. patent protection expired before generic entry, and Singulair lost practical market exclusivity in the United States after FDA approval of generic montelukast products.

The key commercial point is that current opportunity does not depend on reviving the original montelukast molecule patent. It depends on obtaining separate protection for:

• A novel taste-masking composition.
• A specific particle-size or coating architecture.
• A stable granule or sachet system.
• An orally disintegrating tablet with defined excipient ranges.
• A low-moisture formulation with improved stability.
• A manufacturing process that reduces impurities or improves content uniformity.
• A combination of montelukast with a defined delivery device or packaging system.

Any new patent must satisfy novelty, non-obviousness, enablement, written description, and patentable subject-matter requirements. Broad claims covering routine use of mannitol, MCC, magnesium stearate, or standard sweeteners are likely to face significant validity risk.

Are basic montelukast excipients patentable?

Routine excipient substitution is usually weak subject matter. A stronger patent case requires a measurable technical effect, such as:

• A defined reduction in bitterness or metallic aftertaste.
• Improved dissolution after storage at elevated humidity.
• Reduced degradation impurity formation.
• Better dose uniformity in low-dose granules.
• Improved flow through high-speed sachet-filling equipment.
• Enhanced tablet hardness without delayed disintegration.
• A clinically relevant improvement in adherence or administration success.

Patent claims should connect excipient composition to a reproducible product attribute. A claim that only recites a familiar filler, binder, lubricant, and flavor may provide limited protection against design-around.

When did Singulair lose exclusivity and what is the current Orange Book status?

Singulair's core U.S. exclusivity ended before the current generic market was established. FDA approved the first generic montelukast products in multiple strengths and dosage forms, including tablets, chewable tablets, and oral granules.[2]

Milestone	Commercial effect
Original montelukast patent protection	Protected Merck's branded product
Pediatric exclusivity period	Extended the effective exclusivity window
FDA generic approvals	Opened tablet and pediatric generic competition
Post-exclusivity market	Shifted value from molecule protection to price, supply, and formulation differentiation

The FDA Orange Book remains the principal source for listed patents, exclusivity codes, and approved reference products.[3] For a current launch decision, the relevant product-specific entries must be checked by dosage form and strength. Expired core patents do not prevent market entry, but an applicant must still evaluate any active listed patent, exclusivity code, regulatory requirement, or litigation event associated with the reference product.

Which companies are challenging Singulair, and what is the Paragraph IV risk?

Generic montelukast is already a mature competitive category. The principal Paragraph IV risk was historical and related to early generic entry before or around expiration of Merck's listed patent rights. Current entrants generally face a lower molecule-patent barrier but can encounter formulation, regulatory, supply-chain, or market-access barriers.

For a new applicant, Paragraph IV analysis should focus on:

1. Active patents listed for the specific reference product.
2. Whether the proposed formulation practices a listed claim.
3. Whether the applicant can file a Paragraph IV certification.
4. Whether a patent owner can trigger a 30-month stay under the Hatch-Waxman framework.
5. Whether the product is commercially meaningful enough to justify litigation.

A conventional 10 mg tablet is unlikely to support a high-value patent dispute when several generic alternatives are already available. A differentiated pediatric granule, taste-masked product, or novel orally disintegrating tablet could create a separate patent position, but the value depends on actual market adoption.

What FDA regulatory requirements apply to montelukast excipients?

Montelukast generic products are generally approved through the abbreviated new drug application pathway. The applicant must demonstrate pharmaceutical equivalence and bioequivalence to the relevant reference product, comply with current good manufacturing practice requirements, and provide appropriate inactive-ingredient information.[4]

Excipient regulatory issues

Key FDA considerations include:

• Use of excipients with established oral safety precedent.
• Compliance with the FDA Inactive Ingredient Database where applicable.
• Evaluation of maximum daily exposure for pediatric products.
• Control of elemental impurities and residual solvents.
• Allergen and intolerance labeling.
• Flavor and sweetener acceptability.
• Microbial controls for powders and granules.
• Packaging suitability for moisture-sensitive products.
• Product-specific dissolution and stability testing.

A change in excipient composition can affect dissolution, absorption, taste, tablet disintegration, and bioequivalence. The risk is highest in low-dose pediatric products, where the excipient-to-drug ratio is large.

Aspartame and phenylalanine labeling

Aspartame-containing chewables require appropriate phenylalanine labeling. An aspartame-free product can simplify labeling for some populations, but the replacement sweetener must be evaluated for taste, stability, regulatory status, and pediatric exposure.

Lactose labeling

Lactose-containing tablets are commercially standard, but lactose-free products can target patients with lactose intolerance or customers who prefer excipient-minimized products. The clinical value of lactose avoidance must be communicated accurately. The formulation claim should not imply that ordinary tablet lactose exposure causes intolerance in all patients.

What commercial opportunities exist for excipient suppliers?

Excipient suppliers can participate at several levels.

Pediatric taste-masking systems

Taste masking is the clearest value opportunity. Montelukast is administered to young children, and bitterness or lingering aftertaste can reduce adherence. Suppliers can offer:

• Polymer-coated montelukast particles.
• Ion-exchange resin complexes.
• Lipid or wax-based taste-masking systems.
• Spray-dried flavor matrices.
• Sweetener-flavor combinations optimized for montelukast.
• Granule coatings that preserve immediate release.

The most valuable products will provide data on bitterness reduction, dissolution, stability, and manufacturing scale-up rather than only a list of ingredients.

Co-processed excipients

Co-processed fillers can reduce formulation development time by combining binding, flow, disintegration, and compactability in one platform. This is relevant to high-speed production of 10 mg tablets and pediatric chewables.

Potential benefits include:

• Lower lubricant sensitivity.
• Better weight uniformity.
• Reduced tablet capping.
• Improved mechanical strength.
• More consistent disintegration.
• Simplified raw-material handling.

The supplier's commercial advantage depends on consistent lot performance and regulatory documentation.

Sweetener and flavor systems

Cherry flavor is associated with the reference chewable product. A generic manufacturer can differentiate with berry, fruit punch, or neutral flavor systems, subject to patient testing and regulatory requirements. Flavor replacement is not automatically a strong patent opportunity because it is often considered routine unless supported by unexpected technical results.

High-barrier packaging

Excipient strategy cannot be separated from packaging. Sachet granules and chewable tablets may require:

• Aluminum laminate sachets.
• High-density polyethylene bottles with desiccants.
• Child-resistant closures.
• Unit-dose packaging.
• Low-moisture blister systems.

Packaging improvements can produce a practical market advantage even when the formulation is not strongly patentable.

How does Singulair compare with competing asthma and allergy products?

Montelukast competes with inhaled corticosteroids, antihistamines, intranasal corticosteroids, and combination products. Its excipient opportunity is distinct because it is an oral pediatric product rather than an inhaled delivery system.

Product category	Main differentiation	Excipient opportunity
Montelukast chewable	Taste and ease of administration	Sweeteners, flavors, disintegration
Montelukast granules	Infant and young-child dosing	Taste masking, sachet performance
Inhaled corticosteroid	Lung deposition	Carrier particles, propellants, device compatibility
Oral antihistamine	Dosing convenience	Syrup viscosity, preservatives, flavor
Intranasal steroid	Local delivery	Suspension stability, spray performance

Montelukast does not compete primarily through a novel delivery device. Its commercial advantage is oral convenience, which makes excipient performance particularly important in pediatric adherence.

What generic launch scenarios exist for montelukast?

Low-cost conventional launch

A company can launch a standard 10 mg tablet using established excipients and compete on price, supply reliability, formulary access, and manufacturing scale. This is the lowest technical-risk path and the most exposed to price erosion.

Pediatric adherence launch

A company can target 4 mg and 5 mg chewables with better taste, lower friability, reduced tablet residue, or an aspartame-free profile. The product can support higher margins if the differentiation is accepted by caregivers, pharmacists, and payers.

Granule and sachet launch

A 4 mg granule product can target young children who cannot chew tablets. Unit-dose packaging, clear administration instructions, and food compatibility can create commercial value. The market is smaller than the adult tablet market, but competition may be less commoditized.

Premium excipient platform

A formulation company can license a taste-masking or orally disintegrating technology to a generic pharmaceutical manufacturer. The deal structure could include an upfront payment, development milestones, technology-transfer fees, and royalties on net sales. The licensor's leverage depends on whether the technology is necessary for approval or only provides a marketing advantage.

What geographic markets offer the best opportunity?

The United States offers a large regulatory and commercial market but has intense generic competition. Europe has fragmented national procurement and reimbursement systems, making local market access important. Emerging markets may value pediatric sachets, stable products that tolerate distribution stress, and lower-cost formulations.

Geographic strategy should consider:

• Local excipient approvals.
• Country-specific flavor and sweetener restrictions.
• Pediatric labeling requirements.
• Pharmacopoeial standards.
• Climatic stability zones.
• Local manufacturing incentives.
• Import controls and supply-chain reliability.
• Trademark constraints around Singulair branding.

A formulation that is optimized for U.S. FDA requirements may require additional documentation for European, Japanese, or other regulatory authorities. Excipient suppliers with global regulatory packages can reduce filing friction.

How strong is the patent estate for a new montelukast excipient product?

The legacy montelukast estate is weak as a barrier to generic entry because the primary exclusivity period has ended. A new product's patent strength would depend on the formulation claims, supporting data, and practical difficulty of designing around the claims.

Patent concept	Likely strength
Montelukast plus common tablet excipients	Low
Specific taste-masking coating with validated performance	Moderate
Narrow granule composition with stability and dissolution data	Moderate
Broad claim to any flavored montelukast chewable	Low
Manufacturing process producing a defined impurity profile	Moderate to strong if difficult to replicate
Packaging-only claim	Usually limited unless technically novel
Orally disintegrating composition with unexpected performance	Moderate, subject to evidence

The most defensible strategy combines composition claims, process claims, product-by-process limitations where appropriate, and measurable performance specifications. Patent term should be synchronized with regulatory approval and commercial launch. A late-filed patent may have limited economic value if generic competitors can enter with conventional formulations.

What litigation and settlement issues affect Singulair?

The major litigation period concerned early generic challenges to Merck's montelukast patent protection. With generic products already approved, current commercial disputes are more likely to involve:

• ANDA litigation over a newly listed formulation patent.
• Trade dress or trademark disputes.
• Product liability claims.
• Supply and manufacturing agreements.
• Antitrust issues involving delayed generic entry or settlement terms.
• Patent disputes over pediatric formulations or taste-masking technology.

Any proposed licensing or acquisition should review historical settlement agreements, Orange Book listings, FDA approval letters, patent assignment records, and litigation databases. The economic value of a settlement depends on whether it preserves meaningful market exclusivity or only delays entry into an already crowded category.

Key Takeaways

• Singulair is an established montelukast product with no biosimilar issue and extensive generic competition.
• The main formulations are 10 mg film-coated tablets, 4 mg and 5 mg chewables, and 4 mg oral granules.
• Pediatric excipients create the strongest commercial differentiation through taste masking, sweetener selection, granule performance, and adherence.
• Aspartame-free and lactose-free products are viable positioning concepts but require careful technical and regulatory substantiation.
• Conventional excipient substitutions have limited patent strength unless linked to unexpected performance.
• The highest-value IP opportunities involve taste-masking compositions, stable granule systems, orally disintegrating tablets, and manufacturing processes.
• A standard adult tablet is a low-risk, low-margin opportunity. Pediatric chewables and granules offer greater differentiation but carry higher formulation and palatability risk.
• High-barrier packaging, co-processed excipients, and global regulatory support can create commercial value even without strong product patent protection.

FAQs

Is montelukast sodium compatible with lactose-free formulations?

Yes. Lactose is used in certain reference tablet formulations, but lactose-free montelukast tablets can be developed with mannitol, microcrystalline cellulose, calcium phosphate, or co-processed fillers, subject to formulation and bioequivalence testing.

Can an excipient supplier patent a montelukast taste-masking system?

Yes, if the composition and performance are novel and non-obvious. Stronger claims usually require defined coating materials, particle attributes, dissolution behavior, and demonstrated taste-masking results.

Is an aspartame-free Singulair alternative commercially attractive?

It can be attractive in pediatric and specialty markets, especially for patients who require avoidance of phenylalanine. The commercial opportunity is narrower than the general generic market and depends on achieving acceptable taste with an alternative sweetener system.

Do montelukast oral granules require a different manufacturing strategy from chewable tablets?

Yes. Granules require control of particle size, flow, segregation, dose uniformity, moisture, taste masking, and sachet filling. Chewable tablets require greater focus on compression, hardness, friability, mouthfeel, and disintegration.

Can a new montelukast formulation receive regulatory exclusivity?

A formulation may qualify for protection through a new drug application or other regulatory pathway if it meets applicable requirements, but regulatory exclusivity is distinct from patent protection. The scope depends on the formulation, clinical data, labeling, and FDA determination.

References

1. U.S. Food and Drug Administration. (2024). Singulair (montelukast sodium) prescribing information. Merck Sharp & Dohme LLC. https://www.accessdata.fda.gov/drugsatfda_docs/label/

2. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs, Singulair and montelukast products. https://www.accessdata.fda.gov/scripts/cder/daf/

3. U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

4. U.S. Food and Drug Administration. (2024). ANDA submissions: Content and format of an abbreviated new drug application. https://www.fda.gov/drugs/generic-drugs/abbreviated-new-drug-application-anda

5. U.S. Food and Drug Administration. (2024). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/cder/iig/